Revenue Is Not Health

Revenue is one of the cleanest numbers in live music. It is also one of the easiest to overinterpret. A dollar is comparable across venues and tours in a way that cultural relevance, audience trust or local scene vitality are not. Public companies report revenue under standardized accounting rules, trade publications rank tours by gross, and promoters settle shows in financial terms. Any serious analysis of the business should begin with revenue. The mistake is allowing the number to answer questions it was not designed to answer.

Live Nation Entertainment reported $25.2 billion in consolidated 2025 revenue, including $20.9 billion from its Concerts segment, and reported 159 million concert attendees across approximately 55,000 live-music and other events.¹ Pollstar’s year-end analysis found that the average ticket price among the top 100 touring artists was $135.92 in 2024, 41.3 percent above 2019.² At the same time, NIVA reported that 64 percent of independent stages were not profitable in 2024.³ The combined picture suggests a market in which large-scale demand and financial throughput can coexist with weak profitability in parts of the infrastructure.

A simple revenue identity makes the point. Ticket revenue is approximately equal to paid attendance multiplied by average realized ticket price. A 20 percent increase in revenue can result from a 20 percent increase in attendance with stable prices, a 20 percent increase in average price with stable attendance, or some combination. Those scenarios have different implications for access and market development. If participation expands broadly, more people are entering the live economy. If participation is flat and revenue rises through premiumization, the business is monetizing existing demand more intensively.

Neither scenario is inherently superior. Pricing scarce inventory to demand can improve artist and promoter economics and reduce the arbitrage captured by resellers. Premium products can subsidize lower-priced inventory. Higher prices may be necessary when production, labor, insurance and artist costs rise. The analytical problem is not that revenue increases; it is that the source of the increase is often omitted from claims about industry health.

The same issue appears in venue economics. A market can report higher total concert grosses while losing small rooms, because high-capacity events can dominate aggregate spending. If a stadium adds one major tour weekend while several 300-capacity venues close, regional ticket revenue may rise even as the development ladder for emerging artists becomes thinner. Aggregate revenue records the money, not the topology of the market.

This is why Live Index separates output measures from system measures. Output measures include gross ticket sales, attendance, revenue per show and average ticket price. System measures include venue survival, capacity distribution, profitability, fan affordability, touring costs, concentration and the ability of artists to move between stages of development. Output tells us how much economic activity occurred. System measures tell us something about the conditions under which future activity can occur.

The distinction is well established outside music. A national economy can grow while particular regions or households stagnate. A hospital system can increase revenue while access deteriorates. An airline can improve yield while serving fewer passengers on a route. Revenue remains real and important, but its distribution and mechanism matter.

The top of the concert market is particularly capable of producing large revenue movements because scarce superstars have enormous pricing power. Stadium tours can aggregate demand across regions and sell premium inventory at prices that would be impossible for most artists. That is an economic success for the participants involved. It does not necessarily imply that a mid-level artist can profitably move from a 500-capacity club to a 1,500-capacity theater, or that an independent festival can absorb a year of rising insurance and production costs.

Pollstar’s 2026 midyear analysis complicates the picture further. Its Top 100 Worldwide sample posted record aggregate gross and ticket sales while the average ticket price slipped to $119.92; in North America, the corresponding average was $122.15, down 2.4 percent year over year, while per-show gross and ticket-sales averages also declined.⁴ The combination argues against a one-directional account of pricing or demand: aggregate business can expand because more shows are reported even while average economics per show soften, so a health index has to distinguish volume growth from changes in per-event performance.

Consumer purchasing power is another necessary denominator. The Bureau of Labor Statistics reported that the combined admissions category for movies, theaters and concerts increased 105 percent from 2000 through 2025.⁵ Median weekly earnings for full-time wage and salary workers were $1,204 in 2025.⁶ These series are not directly comparable to Pollstar’s top-tour ticket data, but they illustrate why affordability should be calculated as a ratio between the cost of attendance and available income rather than as a ticket-price series alone.

There is also a distributional issue. Average price can rise because the entire inventory becomes more expensive, because the mix shifts toward more expensive events, or because a relatively small share of premium seats becomes dramatically more expensive. Those patterns create different consumer experiences. A proper affordability dataset should therefore track medians and price distributions where possible, not merely averages.

The most useful interpretation of record revenue is consequently narrower than industry rhetoric often allows. Record revenue means more money moved through the measured part of the system than before. It can indicate strong demand, improved pricing, greater scale or a richer product mix. Whether it indicates a healthier cultural economy depends on additional evidence.

Live Index will treat revenue as a necessary but insufficient variable. A composite market-health framework should ask whether rising revenue coincides with increasing participation, stable or improving affordability, viable venues at multiple scales, sustainable touring economics and competitive pathways for organizers. When those measures move together, growth is broad. When they diverge, the divergence is the story.